Coming-of-Age of Antibodies in Cancer Therapeutics.

Antibody-based therapies have garnered considerable success in recent years. This is due to the availability of strategies to successfully engineer antibodies into humanized forms, better understanding of the biological processes involved in cancer development, the availability of novel recombinant antibody formats, better antibody selection platforms, and improved antibody conjugation methodologies. Such achievements have led to an explosion in the generation of antibodies and antibody-associated constructs for the treatment of cancer and other diseases. In this review, we critically assess recent trends in the development and applications of bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and immune checkpoint inhibitors (ICIs) as cancer therapeutics. We also highlight recent US FDA approvals and clinical trials of antibody-based cancer therapies.

[1]  P. Parren,et al.  A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. , 2016, Cancer research.

[2]  W. Hiddemann,et al.  CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. , 2014, Blood.

[3]  Y. Kong,et al.  Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1 , 2014, Front. Immunol..

[4]  D. Nagorsen,et al.  Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer , 2015, Expert opinion on biological therapy.

[5]  J. Infante,et al.  Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies , 2014, Drugs.

[6]  J. Ribera,et al.  Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia , 2015, OncoTargets and therapy.

[7]  S. Demaria,et al.  Combination of radiotherapy and immune checkpoint inhibitors. , 2015, Seminars in radiation oncology.

[8]  César Milstein,et al.  Man-made antibodies , 1991, Nature.

[9]  Jinming Yu,et al.  Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. , 2015, Cancer letters.

[10]  H. Pandha,et al.  Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015 , 2015, Cancer Immunology, Immunotherapy.

[11]  S. Sahasranaman,et al.  Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy , 2016, Journal of clinical pharmacology.

[12]  Sahana Bose,et al.  Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin , 2007, Nature Biotechnology.

[13]  J. Hess,et al.  The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. , 2009, Cancer research.

[14]  Guy Georges,et al.  Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies , 2011, Proceedings of the National Academy of Sciences.

[15]  W. Strohl.  Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters , 2015, BioDrugs.

[16]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[17]  J. Tibbitts,et al.  Pharmacokinetic Considerations for Antibody Drug Conjugates , 2012, Pharmaceutical Research.

[18]  Helen X. Chen,et al.  Immune checkpoint inhibitors in clinical trials , 2014, Chinese journal of cancer.

[19]  M. Atkins,et al.  Cancer Immunotherapy: Past Progress and Future Directions. , 2015, Seminars in oncology.

[20]  G. Frantz,et al.  Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. , 2009, Cancer research.

[21]  C. Obinger,et al.  Stability assessment on a library scale: a rapid method for the evaluation of the commutability and insertion of residues in C-terminal loops of the CH3 domains of IgG1-Fc , 2013, Protein engineering, design & selection : PEDS.

[22]  A. Thakur,et al.  “NextGen” Biologics: Bispecific Antibodies and Emerging Clinical Results , 2016, Expert opinion on biological therapy.

[23]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[24]  D. Goldenberg,et al.  Designing immunoconjugates for cancer therapy , 2012, Expert opinion on biological therapy.

[25]  P. Parren,et al.  High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe , 2016, Journal of biomolecular screening.

[26]  R. Kimmig,et al.  MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. , 2006, Molecular immunology.

[27]  P. Kufer,et al.  BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.

[28]  D. Stephany,et al.  Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies , 1984, The Journal of experimental medicine.

[29]  B. Schoeberl,et al.  MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors , 2013, Molecular Cancer Therapeutics.

[30]  Junjia Zhu,et al.  Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer , 2016, Oncotarget.

[31]  S. Peng,et al.  A sugar engineered non-fucosylated anti-CD40 antibody, SEA-CD40, with enhanced immune stimulatory activity alone and in combination with immune checkpoint inhibitors. , 2015 .

[32]  U. Brinkmann,et al.  Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates. , 2016, Current cancer drug targets.

[33]  U. Brinkmann,et al.  Bispecific digoxigenin-binding antibodies for targeted payload delivery , 2011, Proceedings of the National Academy of Sciences.

[34]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[35]  K. Garber.  Bispecific antibodies rise again , 2014, Nature Reviews Drug Discovery.

[36]  R. Scheller,et al.  Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. , 2008, Journal of immunological methods.

[37]  Rachel M. Webster.  The immune checkpoint inhibitors: where are we now? , 2014, Nature Reviews Drug Discovery.

[38]  H. Lyerly,et al.  CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1 , 2015, Cancer Immunology, Immunotherapy.

[39]  Stephen C Alley,et al.  Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.

[40]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[41]  R. Kontermann.  Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.

[42]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[43]  M. Postow,et al.  Checkpoint blocking antibodies in cancer immunotherapy , 2014, FEBS letters.

[44]  L. Friberg,et al.  A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer , 2014, The AAPS Journal.

[45]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[46]  M. Friedrich,et al.  Highly Efficient Elimination of Colorectal Tumor-Initiating Cells by an EpCAM/CD3-Bispecific Antibody Engaging Human T Cells , 2010, PloS one.

[47]  David C. Smith,et al.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Borzilleri,et al.  Antibody-drug conjugates: current status and future directions. , 2014, Drug discovery today.

[49]  M. Friedrich,et al.  Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens , 2012, Molecular Cancer Therapeutics.

[50]  L. Kuyper,et al.  Site-specific Conjugation on Serine → Cysteine Variant Monoclonal Antibodies* , 2000, The Journal of Biological Chemistry.

[51]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[52]  A. Nisonoff,et al.  Quantitative Estimation of the Hybridization of Rabbit Antibodies , 1962, Nature.

[53]  R. Kefford,et al.  Immune checkpoint inhibitors in melanoma. , 2015, Melanoma management.

[54]  Robert Lyon,et al.  Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index , 2008, Molecular Cancer Therapeutics.

[55]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[56]  J. Wolchok,et al.  Immune modulation in cancer with antibodies. , 2014, Annual review of medicine.

[57]  Jinming Li,et al.  Bispecific antibodies and their applications , 2015, Journal of Hematology & Oncology.

[58]  Diego Ellerman,et al.  Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies , 2013, Nature Biotechnology.

[59]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[60]  J. Bluestone,et al.  Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody , 1985, Nature.

[61]  N. James,et al.  A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer , 2001, British Journal of Cancer.

[62]  H. Einsele,et al.  Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody , 2008, Science.

[63]  Paul J Conroy,et al.  A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications , 2013, Trends in Biotechnology.

[64]  S. Thierfelder,et al.  Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. , 1995, Journal of immunology.

[65]  C. Heeschen,et al.  EpCAM/CD3-Bispecific T-cell Engaging Antibody MT110 Eliminates Primary Human Pancreatic Cancer Stem Cells , 2011, Clinical Cancer Research.

[66]  P. Carter,et al.  Alternative molecular formats and therapeutic applications for bispecific antibodies. , 2015, Molecular immunology.

[67]  A. Mackensen,et al.  T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct , 2013, Leukemia.

[68]  N. Popitsch,et al.  CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.

[69]  C. Bokemeyer,et al.  Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. , 2010, Cancer treatment reviews.

[70]  Hermann Einsele,et al.  Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  W. Mcbride,et al.  Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[72]  P. Kufer,et al.  T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct , 2006, Cancer Immunology, Immunotherapy.

[73]  C. Sheridan.  Amgen's bispecific antibody puffs across finish line , 2015, Nature Biotechnology.

[74]  S. Akilesh,et al.  FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.

[75]  Herren Wu,et al.  The CEA/CD3-Bispecific Antibody MEDI-565 (MT111) Binds a Nonlinear Epitope in the Full-Length but Not a Short Splice Variant of CEA , 2012, PloS one.

[76]  L. Gordon,et al.  Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  P. Parren,et al.  Opening the door to innovation , 2014, mAbs.

[78]  C. Pyke,et al.  Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. , 2010, Cancer research.

[79]  C. Porta,et al.  PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.

[80]  A. Scott,et al.  Antibodies in oncology. , 2011, New biotechnology.

[81]  V. Goldmacher,et al.  Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. , 2011, Therapeutic delivery.

[82]  S. Verma,et al.  HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer , 2016, BMC Cancer.

[83]  A. Advani,et al.  Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia , 2013, Clinical pharmacology : advances and applications.

[84]  Andreas Wolf,et al.  Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. , 2012, Blood.

[85]  M. Satoh,et al.  The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology. , 2015, Journal of pharmaceutical sciences.

[86]  M. Lim,et al.  Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches , 2015 .

[87]  P. Sapra,et al.  The next generation of antibody drug conjugates. , 2014, Seminars in oncology.

[88]  M. Pescovitz.  Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89]  J. Wolchok,et al.  Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo , 2015, The Journal of Immunology.

[90]  J. Weber,et al.  Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. , 2015, Seminars in oncology.